Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors

MLA

Lihua Wang, et al. “Abstract CT316: A Phase I Trial of Oral TRC102 (Methoxyamine HCl) in Combination with Temozolomide (TMZ) in Patients with Relapsed Solid Tumors.” Cancer Research, vol. 75, Aug. 2015, p. CT316. EBSCOhost, https://doi.org/10.1158/1538-7445.am2015-ct316.

APA

Lihua Wang, Larry D. Anderson, Khanh T. Do, Howard Streicher, Robert J. Kinders, Richard Piekarz, Shivaani Kummar, Barbara A. Conley, Lamin Juwara, James H. Doroshow, Jerry M. Collins, Priya Balasubramanian, Jennifer Zlott, Elad Sharon, Woondong Jeong, Yvonne Horneffer, & Alice P. Chen. (2015). Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors. Cancer Research, 75, CT316. https://doi.org/10.1158/1538-7445.am2015-ct316

Chicago

Lihua Wang, Larry D. Anderson, Khanh T. Do, Howard Streicher, Robert J. Kinders, Richard Piekarz, Shivaani Kummar, et al. 2015. “Abstract CT316: A Phase I Trial of Oral TRC102 (Methoxyamine HCl) in Combination with Temozolomide (TMZ) in Patients with Relapsed Solid Tumors.” Cancer Research 75 (August): CT316. doi:10.1158/1538-7445.am2015-ct316.